SAB Biotherapeutics (SABS) Profit After Tax (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Profit After Tax data on file, last reported at -$18.9 million in Q1 2026.

• Quarterly Profit After Tax fell 263.09% year-over-year to -$18.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$398429.0 (up 98.84% YoY) and the FY2025 annual result came in at $13.3 million, up 138.92% from the prior year.
• Profit After Tax fell to -$18.9 million in Q1 2026, from -$16.9 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $45.4 million in Q3 2025 to a low of -$22.9 million in Q4 2023.
• A 5-year average of -$5.9 million and a median of -$7.3 million in 2024 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2023 — Profit After Tax sank 845.93% — and 2025, when it surged 539.11%.
• Tracing SABS's Profit After Tax over 5 years: stood at -$7.9 million in 2022, then plunged by 190.26% to -$22.9 million in 2023, then soared by 50.15% to -$11.4 million in 2024, then plunged by 47.97% to -$16.9 million in 2025, then fell by 11.91% to -$18.9 million in 2026.
• The last three Profit After Tax figures came in at -$18.9 million (Q1 2026), -$16.9 million (Q4 2025), and $45.4 million (Q3 2025), per Business Quant data.